As of November 14, 2026, the most recent 5%+ ownership report on RAPT Therapeutics, Inc. names RTW Investments holding 5.9%. No bankruptcy or receivership appears in its SEC Form 8-K filings. This page cites 16 records in all (Schedule 13G/A, February 17, 2026).
Is this your company?
About to sign with, pay or invest in RAPT Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is RAPT Therapeutics, Inc. a real, registered company?
- RAPT Therapeutics, Inc. files with the SEC under CIK 1673772 (its SEC filings).
- Incorporated in Delaware; business address in South San Francisco, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under RAPT Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-14).
- Layoffs: 1 exit or restructuring plan reported on Form 8-K, Item 2.05 (latest filed 2024-07-19, about 47 jobs).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names RTW Investments (filed 2026-02-17).
Who are RAPT Therapeutics, Inc.'s owners and officers?
RAPT Therapeutics, Inc.: incorporated in Delaware; business address in South San Francisco, California; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-05-15).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2025-01-03)
- : Director (Form D, 2025-01-03)
- : Director (Form D, 2025-01-03)
- : Director (Form D, 2025-01-03)
- : Director (Form D, 2025-01-03)
- : Director (Form D, 2025-01-03)
- : Director (Form D, 2025-01-03)
- : Executive Officer (Form D, 2025-01-03)
- : Executive Officer (Form D, 2025-01-03)
- : Executive Officer (Form D, 2025-01-03)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-05-15 | Orbimed Advisors LLC | 0% |
| Schedule 13G/A, 2026-05-15 | Rtw Investments, LP | 0% |
| Schedule 13G/A, 2026-02-17 | Rtw Investments, LP | 5.9% |
| Schedule 13G/A, 2026-02-13 | Deep Track Capital, LP | 0.4% |
| Schedule 13G, 2026-02-09 | Glazer Capital, LLC | 5.36% |
| Schedule 13G/A, 2025-11-14 | Orbimed Advisors LLC | 6.6% |
| Schedule 13G/A, 2025-11-14 | Biotechnology Value Fund L P | 0% |
| Schedule 13G/A, 2025-11-14 | Nantahala Capital Management, LLC | 3.77% |
| Schedule 13G/A, 2025-10-30 | The Vanguard Group | 4.2% |
| Schedule 13G, 2025-10-29 | Forgrowth Iii Pa B.V. | 7.4% |
| Schedule 13G, 2025-08-14 | Nantahala Capital Management, LLC | 5.75% |
| Schedule 13G/A, 2025-08-14 | Redmile Group, LLC | 9.9% |
Questions about who owns RAPT Therapeutics, Inc.
Who owns RAPT Therapeutics, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of RAPT Therapeutics, Inc.: Redmile Group, LLC (9.9%, Schedule 13G/A, filed 2025-08-14), Forgrowth Iii Pa B.V. (7.4%, Schedule 13G, filed 2025-10-29) and Glazer Capital, LLC (5.36%, Schedule 13G, filed 2026-02-09).
Who are the largest shareholders of RAPT Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of RAPT Therapeutics, Inc. on this page are Redmile Group, LLC (9.9%), Forgrowth Iii Pa B.V. (7.4%) and Glazer Capital, LLC (5.36%).
When did Redmile Group, LLC buy into RAPT Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Redmile Group, LLC on this page is the Schedule 13G/A, filed 2025-08-14, reporting 9.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on RAPT Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on RAPT Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on RAPT Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
How much has RAPT Therapeutics, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2025-01-03 | $149.98M | $149.98M |
Acquisitions reported on Form 8-K, Item 2.01: completed an acquisition (2026-03-03).
Red flags found
1 exit or restructuring plan on Form 8-K (latest Form 8-K, 2024-07-19).
Keep reading
More on RAPT Therapeutics, Inc. and the records around it.
The people at RAPT Therapeutics, Inc.
- William Rieflin is also named on 1 other Form D filing: Lycia Therapeutics, Inc. (Jun 2026)
RAPT Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings May 2026
Companies that share a holder
- ForGrowth III PA B.V. also filed stake reports on 4 other companies: Aura Biosciences, Inc. (Oct 2026), Vor Biopharma Inc. (Dec 2025), Crescent Biopharma, Inc. (Dec 2025)
- Redmile Group, LLC also filed stake reports on 18 other companies: FATE THERAPEUTICS INC (Nov 2026), Electra Therapeutics, Inc. (Sep 2026), Neurogene Inc. (Aug 2026)
- ORBIMED ADVISORS LLC also filed stake reports on 38 other companies: Aspen Neuroscience, Inc. (Nov 2026), ArriVent BioPharma, Inc. (Oct 2026), ADARx Pharmaceuticals, Inc. (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/rapt-therapeutics